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1. Introduction  
 
Cladophialophora bantiana is a black fungus with worldwide distribution, but a  general preference for 
warm climates with high humidity [1]. It is a strongly neurotropic fungus which mostly causes life-
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Cladophialophora bantiana is a neurotropic dematiaceous fungus which rarely causes disseminated 
disease. We report a case of proven C. bantiana osteomyelitis in a renal transplant recipient, 
complicated with probable cerebral disease. Stable disease was reached after combined antifungal 
therapies, immune enhancement and amputation of the infected lower limb.  
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threatening cerebral phaeohyphomycosis [1]. A recent review of 124 C. bantiana brain abscess cases 
showed an equal distribution in immunocompetent and immunocompromised hosts with a significantly 
higher mortality in the latter group [2]. Complete excision of the brain lesions in immunocompetent hosts 
led to significant better survival. Non-cerebral C. bantiana infections are extremely uncommon and 
include mainly cutaneous and pulmonary manifestations [1]. In this case report, we describe a C. bantiana 
osteomyelitis in a renal transplant patient. C. bantiana, as well as other dematiaceous fungi, only rarely 
cause osteomyelitis or arthritis [3]. One recent case of a young immunocompetent man with disseminated 
C. bantiana infection reported biopsy proven vertebral osteomyelitis [4]. Another fatal case of C. 
bantiana septic arthritis of the knee was described by Lim et al [5]. C. bantiana bone or joint infection 
with concomitant cerebral infection is a life-threatening disease. In contrast to the two previous reported 
cases, stable disease was reached after combined antifungal therapies, immune enhancement and 
amputation of the infected lower limb.  
 
2. Case  
 
A 34-year-old woman of North African origin, who had undergone kidney transplantation 17 months 
before, presented at day 0 with progressive pain in the left lower leg since 3 weeks. One year before, in 
her homeland, she had suffered a traumatic wound of the same leg, which had resolved spontaneously and 
without sequelae. 
Upon presentation, immunosuppressive treatment consisted of tacrolimus, mycophenolate mofetil (MMF) 
and low dose methylprednisolone. She had been treated with a course of high dose steroids for biopsy-
proven allograft rejection 5 months earlier. Other relevant medical history included new-onset diabetes 
after transplantation and splenectomy following thrombosis of the vena lienalis.  
She presented with a C-reactive protein (CRP) of 61.4 mg/L (reference < 5mg/L) and a normal neutrophil 
count. Graft function was stable with a serum creatinine level of 1.49 mg/dL (reference 0.51-0.95 mg/dL). 
Magnetic Resonance Imaging (MRI) of the left lower limb showed subacute osteomyelitis of the left 
proximal tibia with bifocal Brodie abscesses in the proximal diaphysis.  
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Surgical debridement was performed at day +6 with sampling for bacterial, fungal and mycobacterial 
culture and panbacterial and panfungal PCR (UMD-Universal, Molzym, Germany). Initial bacterial 
culture results revealed growth of three organisms (Staphylococcus capitis, Corynebacterium amycolatum 
and Staphylococcus epidermidis) and anatomopathologically no inflammation was found. Intravenous 
amoxicillin-clavulanic acid (2g BID) was started with careful follow-up. At day +9, panfungal PCR on 
the perioperative sample tested positive. Additional deeper bone biopsy sections showed a chronic 
osteomyelitis with presence of hyphae. Fungal cultures showed a black fungus, which was identified by 
internal transcribed spacer (ITS) sequencing and morphological characteristics as C. bantiana on day +29. 
ITS sequencing was performed in both sequencing directions with primer pairs ITS1/ITS4 and 
ITS86/ITS4. The aligned sequence had closest hit in GenBank with C. bantiana (accession number 
KP131826.1) indicating 98% sequence identity for ITS1 and ITS2 region and showed 100% sequence 
identity with the ITS2 C. bantiana barcode identifier (accession number EU103989) described by 
Heinrichs et al. [6]. In the meantime, the patient had developed neurological symptoms, with progressive 
right-sided weakness and loss of sensibility. Cerebrospinal fluid (CSF) analysis showed normal white 
blood cell count (2.4/µL), normal protein and glucose level. Bacterial and fungal cultures and molecular 
diagnostics for viruses on CSF were negative. Brain MRI revealed acute diffuse encephalomyelitis with 
bilateral thalamic involvement, compatible with cerebral infection (Figure 1).   
Given the location of the lesions, neurosurgical intervention was considered hazardous and no tissue 
biopsy was performed to confirm the diagnosis of cerebral phaeohyphomycosis.  Antifungal treatment 
with oral voriconazole was started on day +30 and amoxicillin-clavulanic acid was stopped. In addition, 
MMF was stopped and lower tacrolimus trough levels were targeted  (6 µg/L). Despite improvement of 
inflammatory parameters and having adequate voriconazole  trough levels of 3.2-6.8 mg/L, new 
neurological symptoms of left-sided paresthesia and stiffness developed. Follow-up brain MRI showed 
progressive disease. Liposomal amphotericin B (3 mg/kg QD) was added to voriconazole  on day +59.  
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Figure 1: T2 weighted brain magnetic resonance imaging shows bilateral diffuse thalamic abnormalities 
with edema in the internal capsules (a). Multiple confluent micronodules with small cystic components 
are seen on a gadolinium enhanced T1 weighted image (b). An area of diffusion restriction, indicated by 
arrows, is noted in the right thalamus on diffusion weighted imaging, reflecting the presence of pus (c,d). 
 
Worsening of the osteomyelitis urged for a second surgical debridement on day +71. All perioperative 
samples again showed the abundant presence of C. bantiana (Figure 2), triggering a complete withdrawal 
of all immunosupressive drugs and transplantectomy. Hemodialysis was started on day +92. 
Unfortunately, clinical assessment and novel imaging showed further disease progression in bone and 
brain.  
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Figure 2: Hematoxylin-eosin stain of tibia bone biopsy (day +71). Granuloma with central hyphae and 
giant cells, surrounded by mononuclear inflammatory cells. Hyphae (blue arrows) are mainly present in 
the cytoplasm of the multinucleated giant cells (red arrows). 
 
Susceptibility testing of the isolate was performed by both Clinical and Laboratory Standards institute 
(CLSI) and European Committee on Antimicrobial Susceptibility testing (EUCAST) broth dilution 
method for voriconazole (minimal inhibitory concentration (MIC) 0.5 mg/L), amphotericin B (MIC <0.5 
mg/L), isavuconazole (MIC  0.25mg/L (CLSI), 4 mg/L (EUCAST)), posaconazole (MIC  0.016 mg/L 
(CLSI), 0.5 mg/L (EUCAST)) and anidulafungin (MIC 0.031 mg/L). Given the unfavorable evolution, 
liposomal amphotericin B - voriconazole therapy was switched to liposomal amphotericin B - 
isavuconazole (200 mg TID on first and second day, then 200 mg QD) combination therapy, reaching 
therapeutic serum isavuconazole through levels (range: 1.6-2.3 mg/mL).  
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Unfortunately, the disease progressed despite adaptation of the antifungal regimen. Local progression in 
the bone, with incipient involvement of the knee joint, urged for above-the-knee amputation of the left leg 
on day +129. Hereafter, isavuconazole was stopped. Oral delayed-release tablets of posaconazole (loading 
dose of 300 mg BID on first day; then 300 mg QD) and intravenous flucytosine (25 mg/kg QD) were 
added to the liposomal amphotericin B therapy, now at a higher dose of 10 mg/kg QD.  
Following surgery there was no recurrence of osteomyelitis, but cerebral lesions further progressed. The 
first serum through level of posaconazole was 1.0 mg/L. The dose of posaconazole was doubled (300 mg 
BID) on day +156, which resulted in posaconazole trough levels ranging from 1.7 to 4.1 mg/L.  Because 
of increased intracranial pressure, methylprednisolone (40 mg TID, intravenously) was associated on day 
+172. Following tapering and stopping steroids on day +224, intracranial overpressure relapsed and 
steroids were restarted.  
Combination antifungal therapy with posaconazole, flucytosine, and liposomal amphotericin B and low 
dose steroids has finally resulted in clinical and radiological stabilization of the cerebral disease, without 
recurrence of osteomyelitis.  Anti-fungal treatment was eventually downgraded to monotherapy with oral 
posaconazole and the patient started an intensive rehabilitation program while obviously continuing thrice 
weekly hemodialysis.  At present (day +539), the patient has regained her ability to walk using a leg 
prosthesis.  
 
 
3. Discussion  
 
We report a case of C. bantiana osteomyelitis in a transplant recipient, with probable cerebral 
involvement. Trauma is the main cause of the rarely described cases of osteomyelitis with melanized 
fungi [1]. Our patient suffered a minor trauma 1 year before presentation. The often indolent 
characteristics of fungal osteomyelitis can explain the absence of symptoms until 3 weeks before 
hospitalization. In cerebral phaeohyphomycosis, C. bantiana is assumed to primarily colonize the lung, 
followed by hematogenous spread to the central nervous system (CNS) [7].  The surgical debridement 
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may have theoretically induced hematogenous spread from bone to brain. However, since initially no 
brain imaging was performed and given the indolent nature of these infections, cerebral involvement may 
have already been present on day 0. Therefore, in non-cerebral C. bantiana infections, cerebral imaging at 
presentation should be considered. 
C. bantiana infection is difficult to treat with a high mortality rate of approximately 70% [8]. Timely 
diagnosis of the fungal infection is important, but the challenging identification of C. bantiana may delay 
start of treatment. Complete surgical excision, combined antifungal therapy and immune enhancement 
seem to be the best treatment option for cerebral phaeohyphomycosis  and fungal osteomyelitis [3,7,8].  
In our patient, surgical bone debridement and finally amputation of the leg resulted in resolution of the 
osteomyelitis. In contrast, treatment of the cerebral lesions relied solely on antifungals since neurosurgical 
resection could not be performed due to the high risk of collateral neurological damage.  
Experience with antifungal treatment is limited to isolated cases or small series, which mostly involved 
amphotericin B, a triazole (itraconazole, voriconazole or posaconazole) and/or flucytosine [3, 7-9].  
Data concerning in vitro susceptibility of C. bantiana isolates and animal studies are sparse, but our in 
vitro susceptibility results of C. bantiana are in accordance with previously reported MICs [9]. 
Posaconazole, isavuconazole and amphotericine B showed the highest in vitro activity, with slightly 
higher MICs for voriconazole. However, voriconazole penetrates good in brain tissue and abscess 
material [10]. In cerebral C. bantiana infections, both successes and clinical failures have been reported 
with voriconazole [1].  
Amphotericin B in mono- or combination therapy showed mixed results [8]. Furthermore, animal models 
showed less activity of amphotericin B compared to itraconazole and posaconazole [11]. In our case, 
association of liposomal amphotericin B  could not stop progression. 
Posaconazole has good in vitro susceptibility concerning C. bantiana, but the in vivo activity in CNS 
infections is not well documented. Only a limited number of clinical cases are available [10]. In murine 
models, brain tissue concentrations of posaconazole were 50% to 80% of those in serum [12,13]. 
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Moreover, animal studies reported better survival outcomes and better reduction of the brains fungal 
burden with posaconazole compared to itraconazole and amphotericin B [11].  
Isavuconazole has low MICs for C. bantiana [9]. Furthermore,  isavuconazole penetrates in the CNS of 
animal models with invasive candidiasis and few cases of successful treatment of cerebral mucormycosis 
are described [14,15]. More animal and clinical data are needed to investigate the role of isavuconazole in 
treating C. bantiana infections.  
Finally flucytosine, also with an excellent CNS penetration, was added to the therapy with posaconazole 
and liposomal amphotericin B [10]. In murine models with disseminated C. bantiana infections 
synergism and prolonged survival were seen when combining posaconazole, flucytosine and micafungin 
[16]. Furthermore, case series of C. bantiana infection reported a better survival with the combination of 
amphotericin B, flucytosine and an azole [7,8].   
In our patient, steroids had an important role in controlling cerebral edema. It remains unclear whether 
this edema was mainly caused by disease progression or by CNS-immune reconstitution syndrome (IRIS) 
after immune enhancement. IRIS, as seen in human immunodeficiency virus (HIV)-infected patients, has 
also been observed in solid organ transplant (SOT) patients with fungal (mainly Cryptococcosis) 
infections. SOT recipients developed IRIS typically 4 to 6 weeks (but until up to 9 months) after initiating 
antifungal therapy and IRIS preferentially manifested in the CNS. No cases of C. bantiana infection 
related IRIS were described. The optimal management of IRIS in SOT recipients remains unknown, but 
based on case reports and series corticosteroids have been suggested  [17].  
Stabilization of the cerebral infection was finally achieved with a combined use of liposomal 
amphotericin B, posaconazole and flucytosine as well as low dose methylprednisolone. 
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